Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | CES1 | P23141 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | THRA | P10827 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10898528 | 0.83 | THRB (0.56) | MAPTSMN1; SMN2L3MBTL1RAB9AKMT2A | |
| SCHEMBL8051337 | 0.83 | SMN1; SMN2 (0.70) | MAPTSMN1; SMN2L3MBTL1RAB9AKMT2A | |
| SCHEMBL507985 | 0.83 | HSD17B3 (0.62) | SMN1; SMN2L3MBTL1CES2CES1THRA | |
| SCHEMBL9237039 | 0.82 | GSK3B (0.64) | CES2CES1GSK3BALDH1A1THRA | |
| SCHEMBL20278348 | 0.82 | MAPT (0.57) | MAPTSMN1; SMN2L3MBTL1RAB9AKMT2A | |
| SCHEMBL10587394 | 0.82 | SMN1; SMN2 (0.57) | MAPTSMN1; SMN2L3MBTL1RAB9AKMT2A | |
| SCHEMBL1687863 | 0.82 | ALDH1A1 (0.64) | MAPTSMN1; SMN2L3MBTL1RAB9AKMT2A | |
| SCHEMBL5630152 | 0.82 | KMT2A (0.60) | MAPTSMN1; SMN2L3MBTL1RAB9AKMT2A | |
| SCHEMBL27878347 | 0.80 | THRA (0.61) | MAPTSMN1; SMN2L3MBTL1KMT2AMEN1 | |
| SCHEMBL13080503 | 0.80 | CES2 (0.55) | L3MBTL1CES2CES1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-60115547-A | — | — | None | — | — | JP | disclosed |
| US-20240408214-A1 | NANOPARTICULATE MONOBENZONE FOR TREATING MELANOMA | NORTHWESTERN UNIVERSITY | 2024-12-12 | — | — | US | disclosed |
| WO-2023049896-A1 | NANOPARTICULATE MONOBENZONE FOR TREATING MELANOMA | NORTHWESTERN UNIVERSITY (US) | 2023-03-30 | — | — | WO | disclosed |
| CN-111377814-A | Preparation method of α -acyloxyketone compound | 河北科技大学 | 2020-07-07 | — | — | CN | disclosed |
| CN-109641890-A | Isocitric dehydrogenase (IDH) inhibitor | 上海迈同生物科技有限公司 | 2019-04-16 | — | — | CN | disclosed |
| CN-105377846-B | Organic compound | 细胞内治疗公司 | 2018-03-20 | — | — | CN | disclosed |
| CN-107082782-A | Substituted xanthine and its application method | 海德拉生物科学有限公司 | 2017-08-22 | — | — | CN | disclosed |
| CN-105143229-B | Substituted xanthines and methods of use thereof | 海德拉生物科学有限公司 | 2017-06-30 | — | — | CN | disclosed |
| CN-105121423-B | 3- (4- (benzyloxy) phenyl) hex-4-ynoic acid derivative, method for preparing the same, and pharmaceutical composition for preventing and treating metabolic diseases comprising the same as an effective ingredient | 现代药品株式会社 | 2017-06-09 | — | — | CN | disclosed |
| CN-106715409-A | Complex preparation for preventing or treating metabolic diseases comprising novel 3- (4- (benzyloxy) phenyl) -4-hexenoic acid derivative and other active ingredients | 现代药品株式会社 | 2017-05-24 | — | — | CN | disclosed |
| US-20080153979-A1 | non-natural amino acids are selected from amino acids having protected or masked carbonyl, dicarbonyl, hydroxylamine, or oxime side chains, and amino acid attached to a polyoxyethylene glycol, acrylic polymers or natural polymer; therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080153979-A1 | non-natural amino acids are selected from amino acids having protected or masked carbonyl, dicarbonyl, hydroxylamine, or oxime side chains, and amino acid attached to a polyoxyethylene glycol, acrylic polymers or natural polymer; therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| US-7385028-B2 | Modified non-natural amino acid polypeptides typically include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group; therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC (US) | 2008-06-10 | — | — | US | disclosed |
| US-7385028-B2 | Modified non-natural amino acid polypeptides typically include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group; therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC (US) | 2008-06-10 | — | — | US | disclosed |
| US-7332571-B2 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332571-B2 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| JP-S60115547-A | P-(HALOMETHYL)PHENYL KETONE AND ITS PRODUCTION | NISSAN CHEM IND LTD | 1985-06-22 | — | — | JP | disclosed |
| US-4265898-A | ANTICOAGULANTS | BAYER AKTIENGESELLSCHAFT (DE) | 1981-05-05 | — | — | US | disclosed |
| US-4053316-A | PHOTOPOLYMERIZATION OF ETHYLENICALLY-UNSATURATED ORGANIC COMPOUNDS | ICI UNITED STATES INC. (US) | 1977-10-11 | — | — | US | disclosed |
| US-3982942-A | MANGANESE CARBONYL CATALYST | ICI UNITED STATES INC. (US) | 1976-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153979-A1 | non-natural amino acids are selected from amino acids having protected or masked carbonyl, dicarbonyl, hydroxylamine, or oxime side chains, and amino acid attached to a polyoxyethylene glycol, acrylic polymers or natural polymer; therapeutic, diagnostic, and other biotechnology uses | DAO, DNPEP, AADAT | MAPT 2518/4885SMN1; SMN2 1676/4885L3MBTL1 1362/4885 |
| US-20240408214-A1 | NANOPARTICULATE MONOBENZONE FOR TREATING MELANOMA | TYR, CD47, SDHB | MAPT 3003/4885SMN1; SMN2 1504/4885L3MBTL1 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.